Generex Publishes Results From Pre-Clinical Studies On Immunotherapeutic Vaccine for HPV-Induced Cervical Cancer

22-Jul-2009 - USA

Generex Biotechnology Corporation announced publication of studies demonstrating the anti-cancer activity of a novel Ii-Key/HPV immunotherapeutic vaccine. The immunotherapeutic vaccine for HPV-induced cancers makes use of the Ii-Key platform technology developed by scientists at Antigen Express, Inc., Generex’s wholly-owned immunotherapeutics subsidiary.

The Antigen Express studies demonstrate that mice immunized with an Ii-Key/HPV16 E7 hybrid show increased killing of cells expressing an HPV-specific antigen, but not control cells lacking the antigen. Consistent with the predicted mechanism of action of the vaccine, HPV-specific activation of CD4+ T helper cells was observed in immunized mice. The first author of the study, Dr. Minzhen Xu, is Vice-President of Biology at Antigen Express.

The current studies demonstrate an additional application of the Ii-Key technology platform being developed at Antigen Express. Currently, another peptide designed with this technology is the subject of three clinical trials: a Phase II trial in breast cancer patients, a Phase I trial in prostate cancer patients, and a separate Phase I trial in breast or ovarian cancer patients wherein it is being tested in combination with another peptide vaccine. That immunotherapeutic vaccine, AE37, couples Ii-Key with a fragment of the HER2 protein, which is expressed in a variety of cancers and is associated with worse prognosis.

While prophylactic vaccines against HPV-induced cervical cancer are available, those vaccines do not benefit patients once cancer has arisen. The difference is that Ii-Key/HPV hybrid vaccines help to induce a cellular immune response, which is necessary for killing cancer cells.

Original publication: “Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers”; Vaccine July 2009, Volume 27, Issue 34

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...